Democracy Dies in Darkness

Lyme disease vaccine shows 70 percent efficacy, Pfizer says

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the first.

Doses Pfizer’s Lyme disease vaccine are prepared in Duncansville, Pennsylvania, in 2022. (Gary M. Baranec/AP)

Four doses of an experimental vaccine to protect against Lyme disease reduced the number of tick-borne infections by more than 70 percent, according to Pfizer and Valneva, the pharmaceutical companies developing the shot.

Subscribe for unlimited access to The Post
Save on unmatched reporting.
Get your first six months for $2 USD every four weeks